DorsaVI

What DorsaVI does

DorsaVI (ASX: DVL) is an Australian-listed biotechnology and motion analysis company founded in 2008 that develops FDA-cleared and TGA-certified wearable sensor systems for clinical, sports, occupational health, and defence applications. The company's core platform comprises ViMove+ (clinical and athletic movement analysis using wireless IMU sensors combining accelerometer, gyroscope, and magnetometer data), ViSafe+ (workplace safety sensors with surface EMG for ergonomic and manual handling risk assessment), Video AI (computer-vision movement analysis module), and Research+ (research-grade motion capture software). The company operates a database of over 10,000 proprietary knee assessments underpinning AI-powered injury-risk analytics, including a 3D knee motion analysis module launched in March 2025 that addresses limitations of traditional 1D force plates for ACL injury risk identification.

DorsaVI monetises through hardware sales of medical-grade wearable sensors paired with subscription and licence-based software (including the Video AI module), supplemented by clinical validation study contracts (e.g., Dr Patel collaboration, SEROMA European study) and emerging technology licensing revenue. Go-to-market is sales-led with 'Request a Demo' and 'Free Trial' CTAs, an online store for SMB and individual buyers, and a distribution partnership with Select Medical Network covering 120+ active clinical sites. The customer base spans SMB physical therapy clinics, sports medicine and elite sport customers, enterprise workplace safety deployments (Heathrow Airport, mining and utilities sectors), and government/defence applications including police tactical units.

Since 2024 the company has executed a significant strategic pivot toward semiconductor and AI hardware, launching wholly owned subsidiary Artemis Labs in August 2025, acquiring neuromorphic processing-in-memory technology from Technion, signing multi-year compute-in-memory RRAM co-development partnerships with ITRI (Taiwan) and NTU (Singapore), licensing exclusive worldwide robotics IP from NTU Singapore in June 2026, and launching the Sensor v6.5 Physical AI wearable in July 2026. The pivot targets robotics, rehabilitation exoskeletons, and ultra-edge AI applications, though FY25 revenue was AU$1.15M (a 14% YoY decline) against AU$3M annual cash burn, and the new lines have not yet produced material commercial revenue.

Name

DorsaVI

Legal name

dorsaVi Ltd

Website

https://dorsavi.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

DorsaVI (ASX: DVL) is an Australian-listed wearable motion analysis company that sells FDA-cleared ViMove+ clinical sensors, ViSafe+ workplace safety sensors, Video AI, and Research+ software to physical therapy clinics, elite sports teams, enterprise occupational health buyers, and defence customers, while pivoting via Artemis Labs toward RRAM semiconductors and robotics IP.

Ownership category

akta.pro rank

Product category

Wearable Movement Analysis Technology

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

Keywords

• Wearable motion sensors
• Movement analysis software
• Workplace ergonomics monitoring
• Clinical rehabilitation technology
• Wearable IMU sensors

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Wearable Sensor Hardware and Software: Medical-grade wearable devices and associated software platforms (ViMove+, ViSafe+, Research+) sold to clinical, sports, and workplace safety customers with recurring software/license components.
2. Video AI Subscription: AI-powered video analysis technology offered as module subscription for movement assessment in gyms, clinics, and sporting clubs.
3. Clinical Validation Contracts: Contracted revenue from clinical validation studies such as Dr Patel collaboration and SEROMA European study validating Ultra Edge platform and on-device AI capabilities.
4. Technology Licensing: Revenue expected from expanded platform into collaborative robotics, rehabilitation exoskeletons and human-augmentation devices following NTU Singapore IP licensing.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

DorsaVi develops and sells FDA-cleared wearable movement analysis systems combining wireless IMU sensors with AI-powered video analysis for clinical rehabilitation, elite sports, workplace safety, and research applications. Its core platform ViMove+ captures objective biomechanical data for return-to-sport and injury prevention decisions, while ViSafe+ addresses occupational ergonomic risk and Research+ supports clinical and academic research. The company is also commercializing Sensor v6.5, an on-device Physical AI wearable, and 22nm RRAM semiconductor technology for robotics and ultra-edge AI.

Product overview

DorsaVI offers a unified movement intelligence platform centred on its FDA-cleared ViMove+ wearable sensor system, supplemented by Video AI (sensorless computer-vision movement analysis), ViSafe+ (workplace safety sensors), and Research+ (research-grade motion capture). The product portfolio operates as a platform-plus-modules architecture: ViMove+ serves as the core clinical and sports sensor, with Video AI providing a complementary sensorless video AI layer; ViSafe+ addresses the occupational health segment; and Research+ targets academic and clinical research. Legacy products (ViMove, ViPerform, myViSafe, Professional Suite) remain supported but are succeeded by the current generation. The company is expanding into adjacent markets through Artemis Labs (robotics/AI subsidiary), RRAM semiconductor technology development, and the Sensor v6.5 Physical AI wearable, as well as a licensed robotics IP portfolio from NTU Singapore for exoskeleton and collaborative robotics applications.

Differentiator

Problem solved

Functional benefit

Brands

• Artemis Labs: Wholly owned subsidiary focused on advancing robotics, artificial intelligence, and sensor technologies, including RRAM semiconductor technology for edge AI and robotics applications.
• ViMove+
• ViSafe+
• Video AI
• Research+

Products and services

• ViMove+ FDA-cleared wireless IMU wearable sensor platform using accelerometer, gyroscope, and magnetometer for clinical and athletic movement analysis, supporting return-to-sport assessment, rehabilitation monitoring, injury prevention, and ACL injury-risk screening in physical therapy, elite sport, and defence applications.
• Video AI AI-powered sensorless video technology that performs running gait analysis and upper/lower limb movement evaluations using computer vision to detect movement angles and provide real-time visual feedback on asymmetries and movement inefficiencies, offered as a module subscription for clinics, gyms, and sporting clubs.
• ViSafe+ Industrial software paired with wearable sensors and sEMG electrodes for comprehensive manual handling assessments, identifying ergonomic risk patterns, detecting muscle fatigue, validating safety interventions, and supporting safer work practices through objective movement data in workplaces such as airports, mining, utilities, and logistics.
• Research+ Advanced research software and wearable sensors with a library of algorithms for dynamic movement assessment, supporting kinematic metrics and EMG integration with flexible sampling configurations for laboratory, field, academic, pharmaceutical, and clinical research applications.
• Sensor v6.5 First commercially-ready Physical AI wearable from dorsaVi that performs movement analysis and delivers real-time biofeedback directly on the device without requiring cloud connectivity or a base device, completing the measure-analyse-decide-act loop within milliseconds at the point of movement, built on the FDA-cleared and TGA-certified movement analysis platform.

Quantifiable outcome

• 53% reduction in manual handling injuries at Heathrow Airport baggage handlers within one year
• +6 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature12 records

Partnerships

Eight partnerships are on record, tiered core, minor and key.

• Nanyang Technological University Singapore (NTU Singapore)coreTechnology or Integration · 10 June 2026DorsaVi signed an exclusive worldwide 10-year licence agreement to acquire two robotics IP assets covering human-robot collaboration safety systems, including a universal control framework and multimodal data collection methodology. Total consideration of SGD 290,000 over the term with no product-sale royalties. Deal positioned to expand platform from wearable sensing into collaborative robotics, rehabilitation exoskeletons and human-augmentation devices.
• Artemis LabscoreStrategic or Co-development Partner · 20 August 2025Wholly owned subsidiary launched by dorsaVi to consolidate R&D efforts in robotics, AI, and sensor technologies, aiming to deliver neuromorphic systems for healthcare and robotics applications. Positioned to integrate FDA-cleared movement analytics with RRAM semiconductor technology.
• ITRI (Taiwan)coreStrategic or Co-development PartnerMulti-year partnership established to develop compute-in-memory RRAM technology targeting robotics and ultra-edge AI applications. Part of dorsaVi's strategic pivot toward semiconductor innovation for next-generation intelligent physical systems.
• NTU (Singapore)coreStrategic or Co-development PartnerMulti-year partnership for RRAM technology development targeting robotics and ultra-edge AI, complementing the robotics IP licensing agreement.
• Technion (Professor Shahar Kvatinsky)coreTechnology or IntegrationAcquisition of neuromorphic processing-in-memory technology from Technion - human brain-inspired computing enabling memory chips to process data simultaneously rather than following energy-intensive Von Neumann model.
• Dr PatelminorStrategic or Co-development Partner8-month clinical collaboration developing lower-limb analytics module for ViMove+ targeting 2026 revenue. Part of Ultra Edge platform validation totaling over A$200,000 in contracted revenue.
• SEROMA Study (European)minorStrategic or Co-development PartnerEuropean clinical study deploying ViMove+ across six sites for axial spondyloarthritis with three pharmaceutical groups using on-device AI for real-time metrics. Part of A$200,000+ contracted revenue validation.
• Select Medical NetworkkeyChannel Partner/ Reseller/ DistributorHealthcare network with over 120 active sites using ViMove+ for clinical movement analysis. Major distribution channel partnership for clinical segment.

Scale indicators17 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Qualisys: Provider of optical and inertial motion capture systems for clinical biomechanics, research, and sports — competing in the Research+ and clinical movement analysis segments alongside DorsaVi.
• Noraxon USA: Provides EMG and IMU-based biomechanics systems used in clinical research, sports, and rehabilitation — comparable to DorsaVi's Research+ and ViMove+ offerings with overlapping customers in physical therapy and sports medicine.
• BTS Bioengineering: Provides gait analysis, motion capture, and EMG systems (including SMART-DX and P-Walk) for clinical rehabilitation and sports performance — directly overlapping with DorsaVi's ViMove+ clinical/sports offering.
• Kinetic: Provides wearable-based workplace injury prevention and ergonomics platform targeting enterprises — directly comparable to DorsaVi's ViSafe+ workplace safety offering with overlapping customers in logistics, manufacturing, and industrial segments.
• Xsens (Movella): Manufacturer of MVN inertial motion capture systems using IMUs for biomechanics, animation, and clinical/research applications — competing technology and use cases as DorsaVi's Research+ and ViMove+ sensors.
• APDM Wearable Technologies (Clario): Makers of Opal wearable inertial sensors for clinical movement assessment in Parkinson's, ALS, MS, and other neurological conditions — directly comparable technology stack and clinical/sports end markets to DorsaVi.
• Delsys: Specialises in surface EMG sensors (Trigno) for clinical research, sports, and rehabilitation — directly comparable to DorsaVi's ViSafe+ sEMG capabilities for muscle activity monitoring in clinical and workplace settings.
• Vald Health: Australian-based clinical biomechanics company offering ForceFrame, NordBord, and HumanTrak wearable/connected systems for physical therapy, sports, and clinical movement assessment — directly competitive with DorsaVi's ViMove+ clinical positioning.

Broad incumbents

• Catapult Sports: Established athlete wearable tracking vendor serving elite sports teams with GPS/IMU-based athlete monitoring — comparable in end market (elite sports) and sensor-based wearable technology, though with a broader portfolio than DorsaVi.

Emerging players

• Tekscan: Manufacturer of pressure mapping systems used in gait, foot biomechanics, and clinical assessment — adjacent technology and clinical/rehab end markets that overlap with DorsaVi's lower-limb and movement analysis use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/dorsavi
• YouTubeyoutube.com/dorsaVi
• Facebookfacebook.com/dorsaVi
• LinkedInlinkedin.com/company/dorsavi
• Instagraminstagram.com/dorsavi

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DorsaVI